摘要
目的探讨125I粒子组织间植入治疗胰腺癌的疗效。方法回顾性分析2005年7月至2008年6月我院采用125I粒子植入治疗的33例胰腺癌患者资料。肿瘤最大径1.5～6.6cm,平均3.7cm。结果粒子植入术后,止痛有效率为60.6%,术后3个月内4例死亡。术后3个月CT复查,部分缓解(PR)8例,疾病稳定(SD)13例,疾病进展(PD)8例,总有效率27.6%。全组生存时间2～19个月,中位生存时间5.1个月,6例仍在随访中。随访中无胰瘘和胃肠道出血等严重并发症,有51粒粒子(18例患者)丢失,11粒粒子(5例患者)出现迁移,移至肠道9粒,肝、脾各1粒,未见放射性肠炎和肝功能改变。结论125I粒子组织间植入治疗胰腺癌在疼痛缓解方面疗效明确,但本组病例Ⅳ期患者较多,未取得较好的疗效,具体疗效还有待于大样本前瞻性队列研究证实。
Objective To assess the therapeutic effect of interstitial implantation with 125^I seeds in treating pancreatic cancer. Methods During the period of July 2005 - June 2008, interstitial implantation with 125^I seeds was performed in 33 patients （22 males and 11 females, mean age 64） with pancreatic cancer. The maximum diameter of the tumor was 1.5 - 6.6 cm （mean 3.7 cm）. The clinical data were retrospectively analyzed. Results The pain relief rate was 60.6%. Four patients died within 3 months. CT re-exam 3 months after the treatment showed that partial response was observed in 8, stabilization in 13 and deterioration in 8 patients. The overall effective rate was 27.6%. No serious complications, such as pancreatic leakage, gastrointestinal hemorrhage, etc. occurred. The median survival time was 5.1 months. In 18 patients, 51 seeds were missing. In 5 patients,11 seeds were migrated, of which 9 moved to intestine, one to liver and one to spleen. Neither radiation enteritis nor hepatic dysfunction developed. Conclusion In the treatment of pancreatic cancer, interstitial implantation with 125^I seeds is very effective in reliving pain, however, a part of patients in staging Ⅳ enrolled in this study respond poorly to the treatment. Therefore, a prospective cohort study with a large sample is required to further verify the efficacy of the treatment.
出处
《介入放射学杂志》
CSCD
北大核心
2009年第4期281-284,共4页
Journal of Interventional Radiology
基金
上海市领军人才培养基金(LJ06006)
上海市科委临床医学重点项目(054119637)
